FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:1488-1493 May 24, 1990 Number 21 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Bone marrow suppression and anemia are frequent side effects of treatment of the acquired immunodeficiency syndrome (AIDS) with zidovudine (formerly azidothymidine [AZT]). We conducted a randomized, double-blind, placebo-controlled clinical trial of recombinant human erythropoietin (100 U per kilogram of body weight thrice weekly by intravenous bolus) in 63 patients with AIDS treated with zidovudine (29 in the erythropoietin group and 34 in the placebo group). Reductions in the number of units of red cells transfused and the number of patients given transfusions per month became apparent in the second and third months of the trial. The reductions were observed in patients with endogenous erythropoietin levels less than or equal to 500 IU per liter at base line, but not in patients whose levels were greater than 500 IU per liter at the beginning of the study. Although the hematocrit and hemoglobin level were not used as the primary criteria of efficacy because the patients received transfusions when their physicians decided that they needed them, a significantly higher rate of increase in the hematocrit was observed in the patients treated with recombinant human erythropoietin whose levels of endogenous erythropoietin were less than or equal to 500 IU per liter (0.00353 points per week) than in the patients given placebo (0.00116 points per week). This effect was not seen in patients with higher levels of endogenous erythropoietin. Serious side effects did not occur more often in the group treated with erythropoietin than in the placebo group. We conclude that recombinant human erythropoietin may be useful in patients with AIDS treated with zidovudine, although the indicators for its use remain to be clarified.

Source Information

University of Miami, Fla.

This article has been cited by other articles:

• Nejad, S. H., Gandhi, R. T., Freudenreich, O. (2009). Clozapine Use in HIV-Infected Schizophrenia Patients: A Case-Based Discussion and Review. Psychosomatics 50: 626-632 [Abstract] [Full Text]  
• Henry, D. H., Bowers, P., Romano, M. T., Provenzano, R. (2004). Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine. Arch Intern Med 164: 262-276 [Abstract] [Full Text]  
• Fisher, J. W. (2003). Erythropoietin: Physiology and Pharmacology Update. Exp. Biol. Med. 228: 1-14 [Abstract] [Full Text]  
• Schett, G., Firbas, U., Fureder, W., Hiesberger, H., Winkler, S., Wachauer, D., Koller, M., Kapiotis, S., Smolen, J. (2001). Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus. Rheumatology (Oxford) 40: 424-431 [Abstract] [Full Text]  
• Bogden, J. D, Kemp, F. W, Han, S., Li, W., Bruening, K., Denny, T., Oleske, J. M, Lloyd, J., Baker, H., Perez, G., Kloser, P., Skurnick, J., Louria, D. B (2000). Status of selected nutrients and progression of human immunodeficiency virus type 1 infection. Am. J. Clin. Nutr. 72: 809-815 [Abstract] [Full Text]  
• Ebert, B. L., Bunn, H. F. (1999). Regulation of the Erythropoietin Gene. Blood 94: 1864-1877 [Full Text]  
• BROCHU, E., LACASSE-M, S., LARIVIÈRE, R., KINGMA, I., GROSE, J. H., LEBEL, M. (1999). Differential Effects of Endothelin-1 Antagonists on Erythropoietin-Induced Hypertension in Renal Failure. J. Am. Soc. Nephrol. 10: 1440-1446 [Abstract] [Full Text]  
• D'Ambra, M. N., Gray, R. J., Hillman, R., Jones, J. W., Kim, H. C., Rawitscher, R., Schnaper, H., Szymanski, I., Vlahakes, G. J., Kaplan, D., Lynch, K. E., Guilfoyle, M., Abels, R. I. (1997). Effect of Recombinant Human Erythropoietin on Transfusion Risk in Coronary Bypass Patients. Ann. Thorac. Surg. 64: 1686-1693 [Abstract] [Full Text]  
• Cazzola, M., Mercuriali, F., Brugnara, C. (1997). Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood 89: 4248-4267 [Full Text]  
• Abels, R. I., Larholt, K. M., Krantz, K. D., Bryant, E. C. (1996). Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer. The Oncologist 1: 140-150 [Abstract] [Full Text]  
• Garton, J. P., Gertz, M. A., Witzig, T. E., Greipp, P. R., Lust, J. A., Schroeder, G., Kyle, R. A. (1995). Epoetin Alfa for the Treatment of the Anemia of Multiple Myeloma: A Prospective, Randomized, Placebo-Controlled, Double-blind Trial. Arch Intern Med 155: 2069-2074 [Abstract]  
• Gitler, B. (1995). Treatment of Hemolytic Anemia Due to Red Blood Cell Fragmentation Using Recombinant Human Erythropoietin. JAMA 274: 300-301 [Abstract]  
• Phair, J. P., Abels, R. I., McNeill, M. V., Sullivan, D. J. (1993). Recombinant Human Erythropoietin Treatment: Investigational New Drug Protocol for the Anemia of the Acquired Immunodeficiency Syndrome: Overall Results. Arch Intern Med 153: 2669-2675 [Abstract]  
• Madura, J. A. (1993). Use of Erythropoietin and Parenteral Iron Dextran in a Severely Anemic Jehovah's Witness With Colon Cancer. Arch Surg 128: 1168-1170 [Abstract]  
• Heller, H. M., Dzieczkowski, J. S. (1993). Case 36-1993- A 28-Year-Old Man with AIDS, Persistent Pancytopenia, and Lymphoma. NEJM 329: 792-799 [Full Text]  
• Tabbara, I. A. (1993). Erythropoietin: Biology and Clinical Applications. Arch Intern Med 153: 298-304 [Abstract]  
• Henry, D. H., Beall, G. N., Benson, C. A., Carey, J., Cone, L. A., Eron, L. J., Fiala, M., Fischl, M. A., Gabin, S. J., Gottlieb, M. S., Galpin, J. E., Groopman, J. E., Hooton, T. M., Jemsek, J. G., Levine, R. L., Miles, S. A., Rinehart, J. J., Rios, A., Robbins, W. J., Ruckdeschel, J. C., Smith, J. A., Spruance, S. L., Starrett, B., Toney, J., Zalusky, R., Abels, R. I., Bryant, E. C., Larholt, K. M., Sampson, A. R., Rudnick, S. A. (1992). Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials. ANN INTERN MED 117: 739-748 [Abstract]  
• McLeod, G. X., Hammer, S. M. (1992). Zidovudine: Five Years Later. ANN INTERN MED 117: 487-501 [Abstract]  
• Welch, H. G., Meehan, K. R., Goodnough, L. T. (1992). Prudent Strategies for Elective Red Blood Cell Transfusion. ANN INTERN MED 116: 393-402 [Abstract]  
• Matsumoto, S. A., Seideman, M. F. (1992). Considerations in the Treatment of Patients With Acquired Immunodeficiency Syndrome at Home. Journal of Pharmacy Practice 5: 158-163 [Abstract]  
• Furie, B., Miller, K. B. (1991). Hematology. JAMA 265: 3128-3130 [Abstract]  
• Mitsuya, H, Yarchoan, R, Broder, S (1990). Molecular targets for AIDS therapy. Science 249: 1533-1544 [Abstract]